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Background: With growing emphasis on health systems strengthening in global health, various health facility
assessment methods have been used increasingly to measure medicine and commodity availability. However, few
studies have systematically compared estimates of availability based on different definitions. The objective of this
study was to compare estimates of medicine availability based on different definitions.
Methods: A secondary data analysis was conducted using data from the Service Provision Assessment (SPA) – a
nationally representative sample survey of health facilities – conducted in five countries: Kenya SPA 2010, Namibia
SPA 2009, Rwanda SPA 2007, Tanzania SPA 2006, and Uganda SPA 2007. For 32 medicines, percent of facilities
having the medicine were estimated using five definitions: four for current availability and one for six-month period
availability. ‘Observed availability of at least one valid unit’ was used as a reference definition, and ratios between
the reference and each of the other four estimates were calculated. Summary statistics of the ratios among the 32
medicines were calculated by country. The ratios were compared further between public and non-public facilities
within each country.
Results: Across five countries, compared to current observed availability of at least one valid unit, ‘reported
availability without observation’ was on average 6% higher (ranging from 3% in Rwanda to 8% in Namibia),
‘observed availability where all units were valid’ was 11% lower (ranging from 2% in Tanzania to 19% in Uganda),
and ‘six-month period availability’ was 14% lower (ranging from 5% in Namibia to 25% in Uganda).
Conclusions: Medicine availability estimates vary substantially across definitions, and need to be interpreted with
careful consideration of the methods used.
Keywords: Medicine availability, Survey methodology, Health facility assessment, Health systemsBackground
With growing emphasis on health systems strengthening
in global health [1,2], health facility assessment methods
are increasingly being used to assess readiness of facilities
to deliver quality services, an aspect of complex health
systems. Measuring the availability of essential medicines at
facilities is one of the core components of these assessments.* Correspondence: ychoi@usaid.gov
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distribution, and reproduction in any mediumHowever, while surveys focusing on the affordability of
medicines tend to follow standardized methodologies [3-5],
health facility assessments have employed a wide variety
of tools and approaches. Availability of commodities, in-
cluding medicines, is defined differently in various facil-
ity assessment surveys. For example, whereas reported
availability by respondents without verification has been
used in approaches geared toward rapid assessment [6-8],
in-depth facility assessment methods validate the reported
response by observing the medicines, verifying the expir-
ation dates [9,10], and collecting further data on stock-out
over an extended period [10].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mates based on different definitions of availability. Under-
standing the magnitude and pattern of differences among
various estimates is important for interpreting facility as-
sessment results. The purpose of this study is to compare
estimates of medicine availability based on different defini-
tions, using data from Service Provision Assessment sur-
veys (SPA) conducted in five sub-Saharan countries: Kenya,
Namibia, Rwanda, Tanzania, and Uganda.Methods
Data
SPA is a national-level survey of formal sector health facil-
ities, providing comprehensive data on availability of ser-
vices at facilities, readiness of facilities to provide essential
health services, and quality of care. SPA is conducted as
part of the MEASURE Demographic and Health Surveys
(DHS) project, supported by the US Agency for Inter-
national Development [11]. Standardized methodologies
and instruments are used, providing comparable data
across time and countries. As with other surveys under
the project, MEASURE DHS provides technical assist-
ance to host country implementing partners to conduct
the assessment, ensuring data quality and comparability,
and SPA data are freely available to the public [11].
SPA covers selected technical elements (e.g., family plan-
ning, maternal and child health, HIV/AIDS, malaria) as well
as cross-element topics, such as infrastructure, infection
control, and human resources at facilities. Typically, SPA is
conducted as a nationally representative sample survey
of facilities – including both public and non-public sec-
tor facilities and ranging from primary health care facil-
ities to tertiary-level hospitals. The sample design allows
calculation of sub-national estimates of indicators by sec-
tor, facility level, and first-level administrative unit. In a
small number of countries with a limited number of facil-
ities, a facility census approach has been used [12].
SPA utilizes four types of data collection tools: facility
inventory, health worker interview, observation of consul-
tations, and exit interviews with clients. Facility inventory
tool collects facility-level information related to infrastruc-
ture, infection management procedures, laboratory diag-
nostic capacity, management practices, and availability
of equipment, commodities and essential medicines. To
assess the availability of the over 110 medicines listed
in the inventory questionnaire, surveyors interview the
facility staff who is in charge of medicines on the day of
the assessment. For each medicine on the list, the facility
staff is first asked if that medicine is stocked at the facility
and available that day. For the medicines that are stocked
and reported to be available, surveyors ask to see them.
Formulation is specified for each medicine, but any ob-
served strength or dosage is coded as available. In eachcountry, brand names for the medicines are used
as appropriate.
Surveyors then verify that at least one unit of each
medicine in stock has a valid expiration date. Given the
broad scope of SPA, it is not practical to verify the expir-
ation date of all observed units for each of the over 110
medicines, particularly in large facilities. However, sur-
veyors conducted a spot check by verifying expiration
dates on all observed units for 32 sentinel medicines, in-
cluding basic medicines to treat infectious diseases preva-
lent in low-resource settings (Table 1).a For each medicine
for which at least one valid unit is observed, surveyors ask
the facility staff if the facility has experienced any stock
outs of the medicine at any time during the six months
preceding the survey. Reported stock-out responses are
not verified against medicine registers or other records.
Data for this secondary analysis came from recent SPA
conducted in five sub-Saharan African countries: Kenya
SPA 2010, Namibia SPA 2009, Rwanda SPA 2007, Tanzania
SPA 2006, and Uganda SPA 2007. A nationally represen-
tative sample of 695, 611, and 491 facilities were assessed
in Kenya, Tanzania, and Uganda, respectively. In Namibia
data were collected from all 411 formal sector facilities. In
Rwanda, data were collected from all public facilities and
a sample of private facilities, and a total of 538 health facil-
ities were assessed.
Measurement and analysis
For the 32 medicines for which expiration dates were
verified on all observed units, four dichotomous variables
were constructed to measure current (i.e., on the day of
assessment) availability: reported availability without ob-
servation or verification of expiration dates – the most
inclusive definition; observed availability of at least one
unit regardless of expiration dates; observed availability
of at least one valid unit; and observed availability where
all units are valid. For each medicine, percent of facil-
ities with the medicine were calculated using the four
different definitions of current availability. ‘Observed
availability of at least one valid unit’ was used as a reference
definition of current availability for two reasons: i) it is the
most restricted definition routinely collected for all medi-
cines assessed in SPA beyond the selected 32 medicines;
ii) it is also the definition currently used in SPA final reports.
In order to assess relative differences between the reference
estimate and each of the other three estimates, a ratio of the
comparison to the reference estimate was calculated.
In addition, a binary variable was constructed to measure
retrospective six-month availability for the 32 medicines:
‘Observed availability of at least one valid unit’ on the day
of survey (i.e. reference definition of current availability)
and no history of stock-out during the six months before
the survey. The stock-out history was based on respon-
dents’ report. For each medicine, percent of facilities with
Table 1 List of the select 32 medicines for which detailed












11 Ketoconazole [oral or topical]
12 Loperamide [oral]
13 Miconazole [vaginal suppository]
14 Norfloxacin [oral]
15 Nystatin [oral]
16 Nystatin [vaginal suppository]
17 Oral rehydration salts
18 Penicillin Benzyl [injection]
19 Penicillin, procaine [injection]
20 Penicillin-V [oral]










31 Rringers lactate [injection]
32 Plasma expander [injection]
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availability. In order to assess the relative difference com-
pared to the reference current availability, a ratio of the
six-month period to the current availability estimate was
calculated.
All analyses were conducted by country. Summary sta-
tistics of the ratios were calculated among the 32 medi-
cines. We further compared distributions of the ratios
by managing authority (public vs. non-public) and facility
level (primary, health center, and hospitals), using T-test.
Non-public facilities include facilities managed by private,
non-governmental organization, and faith-based organi-
zations. Small sample sizes limited analyses by further
breakdown of these facilities. Classification by level followed
country-specific definitions and categories provided in eachof the final SPA reports. Primary facilities are front line
formal health facilities where communities seek basic
ambulatory services and typically include – but not lim-
ited to – clinics, dispensaries, and health posts (see Table 2
for detailed country-specific information).
A small number of facilities that typically do not store
medicines were excluded from all analyses (52 in Rwanda,
9 in Tanzania, and 12 in Uganda). Further, in Tanzania
and Uganda, 1.7% and 5.2% of sampled facilities had mul-
tiple pharmacies or medicine storage rooms. For those, a
medicine was categorized to be available if it was avail-
able in either pharmacy or medicine storage room. Finally,
since SPA was a sample survey in Kenya, Tanzania, and
Uganda, all estimates were adjusted for sampling weight
in these countries. STATA 11.0 statistical software (Stata
Corporation, College Station, TX, USA) was used for the
analysis.
Results
Table 2 presents basic characteristics of facilities in-
cluded in the analysis. The majority of facilities were pri-
mary care facilities or health centers. The overall percent
of facilities that were public varied from 50% in Kenya to
76% in Uganda. Across levels, public facilities were the
majority in most countries (results not shown). In Rwanda,
however, where only 14% of facilities were reported to be
primary-level facilities, 73% of primary-level facilities were
non-public facilities.
Current availability based on the reference definition –
observed availability of at least one valid unit (hereafter
referred to as reference availability), varied greatly across
most of the medicines and countries (Figure 1). Never-
theless, a small number of medicines showed relatively
similar levels across countries. In all five countries, the
availability was lower than 20% for Amoxicillin injectible,
Kanamycin, Miconazole, and Artemisinin, while it exceeded
60% in Doxycycline, Sulfadoxin/Pyrimethamine, and oral
rehydration salts (Figure 1).
Table 3 presents the average of the reference availability
estimates among the 32 medicines by country. Average
availability across the 32 medicines ranged from 32.3% in
Namibia to 44.2% in Rwanda. However, again, availability
varied greatly among the 32 medicines within each country.
Among the 32 medicines, compared to the reference
value, reported availability without observation or verifica-
tion of expiration dates was higher on average by 3% in
Rwanda and by 8% in Namibia (Table 4), with an un-
weighted average of 6% among the five countries. Ob-
served availability of at least one unit regardless of
expiration dates was higher than the reference values
on average by 0.4% in Rwanda and by 7% in Namibia,
with an un-weighted average of 4% among the coun-
tries. There was larger cross-country variation in rela-
tive differences between estimates based on the most
Table 2 Percent distribution of facilities by managing authority and level: by country
Kenya Namibia Rwanda Tanzania Uganda
(n = 695) (n = 411) (n = 486) (n = 602) (n = 479)
Managing authority
mPublic 49.7 74.5 62.1 67.6 76.0
Non-public* 50.3 25.6 37.9 32.4 24.0
Total 100.0 100.0 100.0 100.0 100.0
Level
Hospital 7.3 11.0 8.6 4.1 9.5
Health center 11.5 11.4 77.6 9.1 32.2
Primary† 81.3 77.6 13.8 86.8 58.3
Total 100.0 100.0 100.0 100.0 100.0
Estimates were adjusted for sampling weights in Kenya, Tanzania, and Uganda.
* Non-public facilities include facilities managed by private, non-governmental organization, and faith based organizations.
† Classification of facilities by level followed country-specific definitions and categories provided in each SPA. Primary care facilities included: clinics, dispensaries,
maternity, and stand-alone VCT clinics in Kenya SPA 2010; clinics, free standing VCT, and sick bays in Namibia SPA 2009; dispensaries, health posts, and clinics in
Rwanda SPA 2007; dispensaries and stand-alone VCT clinics in Tanzania SPA 2006, and health center level II in Uganda SPA 2007.
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and the reference values. Availability based on the re-
stricted definition was lower than the reference value by
only 2% in Tanzania but 19% in Uganda.
Retrospective six-month period availability was lower
than the reference definition of current availability by a
wide range of magnitude across countries and medicines.
Among the 32 medicines, the six-month availability esti-
mates were lower than the current availability estimates
on average by 25% in Uganda but only by 5% in Namibia
(Table 4). Further, within each country, there was a sub-
stantial range of relative differences between the six-monthFigure 1 Current availability of the select 32 medicines in the five stu
observed on the day of survey. Square is a mean estimate among the fiperiod and current estimates among the 32 medicines,
except in Namibia (Figure 2).
By managing authority, in all countries except Uganda,
there were no statistically significant differences in refer-
ence current availability (Table 5) or relative differences
in current availability among the 32 medicines (Table 6).
In Uganda, however, current availability of the 32 medi-
cines was 28.1% in public facilities and 49.1% in non-
public facilities (Table 5), and current availability based
on the most restricted definition (i.e., all observed units
are valid) was on average 26% lower than the reference
value in public facilities – significantly larger than thedy countries: percent of facilities with at least one valid unit
ve surveys. Vertical lines represent a range for each medicine.
Table 3 Estimates of current availability (%) of 32
medicines based on the reference definition*: by country
Mean Median SD Min Max
Kenya 35.4 31.9 26.9 0.8 83.5
Namibia 32.3 21.3 32.1 0.3 93.1
Rwanda 44.2 49.9 34.1 0.2 87.2
Tanzania 36.4 22.4 33.6 0.2 87.6
Uganda 33.1 25.6 29.5 0.0 87.3
*Reference definition: at least one valid unit observed at the facility on the day
of survey.
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Tanzania, and Uganda, public facilities had significantly
larger differences than non-public facilities in relative
differences between six-month availability and current
availability among the 32 medicines (Table 6).
By facility level, reference current availability was signifi-
cantly higher in hospitals compared to that in primary fa-
cilities in most countries, although the difference was only
marginally significant in Uganda (Table 5). In general,Table 4 Relative differences in estimates compared to referen



























*Reference value: percent of facilities with at least one valid unit observed on the d
†In Uganda, the reference estimate was zero for one medicine and statistics are amrelative differences in current availability among the 32
medicines tended to be larger in primary facilities, com-
pared to those in hospitals (Table 6).
Discussion
Given the growing emphasis on monitoring and evalu-
ation of health systems strengthening programs in de-
veloping countries, understanding how to interpret and
compare findings from various health facility assessments
has taken on added importance [1,13]. This study, a sec-
ondary analysis of SPA conducted in five sub-Saharan
African countries, systematically compared estimates of
medicine availability using five definitions of availability
(four of current availability and one six-month availability).
Our results show that estimates of current availability
vary substantially depending on how it is defined. Com-
pared to ‘observed availability of at least one valid unit’,
the reference definition used in this study, availability
of medicines based solely on reported response was on
average 6% higher across the five countries, while observedce estimates* among 32 medicines: by country
Ratio: comparison-to-reference
n Median SD Min Max
2 1.016 0.121 1.002 1.503
8 1.026 0.194 1.000 2.000
2 1.009 0.065 1.000 1.273
1 1.011 0.169 1.000 1.846
5 1.010 0.180 1.000 2.000
4 1.013 0.122 1.000 1.503
1 1.009 0.195 1.000 2.000
4 1.000 0.016 1.000 1.091
2 1.002 0.171 1.000 1.846
9 1.000 0.036 1.000 1.196
0 0.973 0.245 0.000 1.000
9 0.976 0.242 0.000 1.000
3 0.856 0.069 0.719 1.000
1 0.985 0.019 0.924 1.000
5 0.831 0.095 0.498 1.000
4 0.853 0.067 0.742 0.986
1 0.960 0.060 0.667 1.000
9 0.908 0.171 0.000 1.000
0 0.877 0.097 0.568 1.000
8 0.762 0.172 0.000 1.000
ay of survey.
ong 31 medicines.
Figure 2 Boxplot of ratios of six-month to current* availability estimates among 32† medicines: by country. Note: Interquartile range: 0.03 in
Namibia; 0.09 in Kenya, Rwanda, and Tanzania; and 0.12 in Uganda. Reference value: percent of facilities with at least one valid unit observed on the
day of survey. † In Uganda, the reference estimate was zero for one medicine and statistics are among 31 medicines.
Choi and Ametepi BMC Health Services Research 2013, 13:266 Page 6 of 8
http://www.biomedcentral.com/1472-6963/13/266availability where all units were valid was 11% lower. In
addition, availability during the six-month period preceding
the survey was 14% lower than the reference. The pattern
and magnitude of relative differences in various current
availability estimates were comparable between public and
non-public facilities in most countries. However, in Kenya,
Tanzania, and Uganda, relative differences between the
six-month availability and reference values were significantly
larger among public facilities than non-public facilities.
Definitions of current availability used in our study pro-
vide rather simple snapshots of medicine availability. The
reference definition of ‘observed availability of at least
one valid unit on the day of assessment’ does not reveal
the presence of expired medicines in the storage area,
which would indicate poor commodity supply manage-
ment practices. Neither the reference nor the more strict
definition of current availability (i.e., observed availability
in which all units are valid) provide any information on
whether facilities currently have a sufficient amount ofTable 5 Estimates of current availability of 32 medicines*: by
Country Sector Level
Public Non-public Primary
Mean SE Mean SE p-value† Mean
Kenya 33.3 5.6 37.7 4.6 0.55 33.2
Namibia 33.2 6.1 28.8 4.5 0.56 27.2
Rwanda 46.1 6.5 41.1 5.4 0.55 22.9
Tanzania 33.5 6.4 42.5 5.6 0.30 35.3
Uganda 28.1 5.2 49.1 5.8 0.009 30.8
SE: standard error.
*Reference definition: at least one valid unit observed at the facility on the day of s
† P-value for t-test of distributions of estimates between public and non-public facimedicines on-hand to meet client needs. Also, current
availability may not be a good proxy for availability over
an extended period, as our results showed a wide range of
variation in six-month period to current availability ratios.
Finally, affordability and rational use of medicines, as well
as the presence of falsified and substandard medicines,
are important aspects of pharmaceutical systems that
cannot be assessed from availability alone.
Nevertheless, in a large scale health facility assessment
such as SPA – with a large sample size to provide sub-
national estimates of indicators across a number of ser-
vices, we believe ‘observed availability of at least one valid
unit’ is the most appropriate definition to measure current
medicine availability. The reference definition has practical
advantages compared to the other definitions assessed in
this analysis. First, compared to the two more inclusive
definitions of current availability (i.e., reported availability,
and observed availability without verifying validity), it
provides more accurate data, while requiring minimalcountry and managing authority (%)
Health center Hospital
SE Mean SE p-value† Mean SE p-value†
4.6 40.3 5.6 0.33 50.9 5.9 0.02
5.8 36.1 6.1 0.29 61.9 6.5 <0.001
3.6 46.0 6.5 <0.001 61.8 6.7 <0.001
6.0 39.0 5.8 0.65 55.1 6.6 0.03
5.3 33.9 5.2 0.68 45.1 5.4 0.06
urvey.
lities. The number of observations is 32 in all subgroups.
Table 6 Relative differences in estimates compared to reference estimates* (ratio) among 32 medicines: by country
and managing authority
Definition Country Managing authority Level
Public Non-public Primary Health center Hospital
n† Mean SE n† Mean SE p-value‡ n† Mean SE n† Mean SE p-value‡ n† Mean SE p-value‡
Current availability
Reported
Kenya 32 1.36 0.24 32 1.02 0.01 0.17 32 1.09 0.04 31 1.02 0.01 0.06 32 1.01 0.00 0.04
Namibia 30 1.09 0.05 32 1.03 0.01 0.20 30 1.08 0.03 26 1.02 0.01 0.12 32 1.01 0.00 0.03
Rwanda 32 1.04 0.01 31 1.02 0.01 0.42 26 1.03 0.01 32 1.05 0.02 0.34 30 1.01 0.01 0.01
Tanzania 31 1.08 0.06 32 1.02 0.00 0.26 31 1.07 0.04 30 1.01 0.00 0.09 31 1.03 0.01 0.33
Uganda 30 1.04 0.02 31 1.04 0.03 0.96 29 1.02 0.01 30 1.04 0.01 0.21 31 1.05 0.03 0.39
Observed, at least one unit regardless of validity
Kenya 32 1.35 0.24 32 1.02 0.00 0.17 32 1.09 0.04 31 1.00 0.00 0.04 32 1.00 0.00 0.04
Namibia 30 1.08 0.05 32 1.02 0.01 0.19 30 1.07 0.03 26 1.02 0.01 0.25 32 1.00 0.00 0.06
Rwanda 32 1.00 0.00 31 1.01 0.00 0.26 26 1.01 0.00 32 1.01 0.00 0.60 30 1.00 0.00 0.03
Tanzania 31 1.07 0.06 32 1.01 0.00 0.27 31 1.06 0.04 30 1.00 0.00 0.13 31 1.01 0.01 0.22
Uganda 30 1.02 0.01 31 1.00 0.00 0.37 29 1.01 0.01 30 1.01 0.01 0.92 31 1.01 0.01 0.84
Observed, all units valid
Kenya 32 0.87 0.05 32 0.89 0.05 0.74 32 0.89 0.05 31 0.91 0.04 0.78 32 0.90 0.04 0.85
Namibia 30 0.91 0.05 32 0.92 0.04 0.91 30 0.89 0.05 26 0.86 0.05 0.63 32 0.92 0.04 0.69
Rwanda 32 0.87 0.01 31 0.83 0.02 0.19 26 0.86 0.03 32 0.85 0.01 0.70 30 0.88 0.01 0.36
Tanzania 31 0.99 0.00 32 0.98 0.00 0.60 31 0.98 0.00 30 0.99 0.01 0.16 31 0.99 0.00 <0.001
Uganda 30 0.74 0.03 31 0.87 0.02 <0.001 29 0.81 0.03 30 0.78 0.04 0.55 31 0.82 0.01 0.65
Six-month period availability
Kenya 32 0.76 0.03 32 0.90 0.01 0.00 32 0.86 0.01 31 0.89 0.02 0.16 32 0.87 0.01 0.39
Namibia 30 0.94 0.02 32 0.97 0.01 0.15 30 0.92 0.03 26 0.93 0.02 0.70 32 0.98 0.00 0.05
Rwanda 32 0.85 0.03 31 0.89 0.02 0.29 26 0.86 0.04 32 0.87 0.03 0.88 30 0.91 0.02 0.26
Tanzania 31 0.80 0.04 32 0.91 0.01 0.01 31 0.86 0.02 30 0.87 0.02 0.81 31 0.90 0.02 0.17
Uganda 30 0.70 0.03 31 0.82 0.03 0.01 29 0.81 0.02 30 0.74 0.03 0.09 31 0.78 0.03 0.43
SE: standard error.
*Reference value: percent of facilities with at least one valid unit observed on the day of survey.
† n is less than 32, when reference estimates were zero for one or more medicines among the 32.
‡ P-value for t-test of ratio distributions compared public facilities or primary facilities.
Choi and Ametepi BMC Health Services Research 2013, 13:266 Page 7 of 8
http://www.biomedcentral.com/1472-6963/13/266additional costs in fieldwork. One of the most important
factors determining implementation cost is the total num-
ber facilities selected and, especially in low-resource set-
tings where transportation can be limited, the number of
facilities that can be visited per day. Once the survey team
is at a sampled facility, the additional time required to
observe medicines and verify the expiration date of one
unit per medicine is typically not long enough to affect
implementation costs. And, compared to the more strict
definition of current availability (verification of the ex-
piration date of every unit), the reference definition can
reduce surveyor fatigue substantially – especially in large
facilities, which is critical for achieving high data quality.
Finally, the six-month period availability definition has
limited value, since it is based on reported responses onever having stock-out. In order to measure period avail-
ability with minimum errors and bias, medicine registers
need to be reviewed for all medicines to obtain the num-
ber of clinic days during the period and presence of medi-
cines on each clinic day. While it is important for facilities
to be able to provide such detailed information for supply
chain management purposes, reviewing such data would
not be feasible for a large-scale health facility assessment.
Balancing these practical advantages and limitations, the
SPA questionnaires have been recently revised to include
only questions that are necessary to calculate estimates
based on the reference current availability defition [10].
Questions regarding verification of all units for selected
medicines and reported six-month stock out were elimi-
nated. The revised questions to assess medicine availability
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latest health facility assessment tool, the Service Avail-
ability and Readiness Assessment (SARA) [14].
There are limitations in our analysis. First, considering
potential recall errors in reporting retrospective six-month
stock-out, the relative difference of 11% between the
current and the six-month period availability estimates
might have been underestimated. Second, relative differ-
ences across estimates in our study, the fairly small dif-
ference between the reported and the observed current
availability in particular, may be limited to surveys collecting
both reported and verified responses. In SPA, surveyors
inform the respondents that they will validate expiration
dates of available units for each medicine. Thus, respon-
dents have little incentive to provide systematically biased
responses; therefore, any difference between reported and
observed availability is likely due to random reporting
errors. However, in assessments that rely on reported
responses only, there may be more reporting bias in
addition to random errors, depending on the objective
and purpose of the assessment. For example, if a health
facility assessment is conducted for monitoring and evalu-
ation of performance based financing programs, there
may be increased incentives to underreport stock-outs.
Finally, in comparison of results by managing authority
and facility level, the small number of medicines could
have contributed to lack of statistical power in spite of
relatively large differences between sub-groups in some
cases. Also, if all or a portion of the 32 medicines are
supplied by the same distributor, availability among
them might be correlated, violating an assumption of
independence among observations for T-test.
Conclusions
In summary, estimates of medicine availability vary sub-
stantially depending on definitions. Observed availability
of at least one valid unit may be an appropriate definition
to be used in a large scale health facility assessment, consid-
ering feasibility and cost of assessments and the limitations
of other definitions. To interpret and compare results from
various facility assessments, users need to consider the
methods and definitions carefully.
Endnotes
aCountry-specific guidelines may vary in terms of whether
these medicines are required at all health facilities. However,
considering the burden of diseases in low-resource settings,
most facilities are expected to have the 32 medicines.
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